IMNMImmunome Inc
$18.22
$0.16
(0.87%)
EarningsAug 6
Mkt Cap$2.08B
Vol95,861.00
Fundamentals
Mkt Cap
$2.08B
Volume
-
52W High
$27.65
52W Low
$7.96
PE Ratio
-7.72
Avg. Volume
1.03M
EPS (Annual)
-$2.43
Rev/Employee
$39,214.69
Earnings
Aug 06
32
Bearish Sentiment
How do you feel about IMNM?
Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that the first patient has been dosed in the Phase 1, first-in-human trial of IM-1617, a potential first-in-class ADC directed at an undisclosed...
Business Wire
4 Biotech Stocks Investors Should Watch in 2026
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position LQDA, IMNM, STOK and IMCR well in this volatile sector.
Zacks
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Immunome, Inc. (the Company) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on June 1, 2026, the Compensation Committee of the Companys Board of Directors (the Compensation Committee) granted inducement...
Business Wire
Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual Meeting
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced detailed efficacy and safety results from RINGSIDE, the global, randomized, double-blind, placebo-controlled Phase 3 trial of varegacestat in...
Business Wire
Immunome to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that members of Immunomes management will present at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, at 10:40 a.m...
Business Wire
What Offers Immunome (IMNM) a Compelling Investment Opportunity?
What Offers Immunome (IMNM) a Compelling Investment Opportunity...
Yahoo! Finance: News
Immunome Reports First Quarter 2026 Financial Results and Provides Business Update
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the quarter ended March 31, 2026, and provided a business update. This quarter reflects the progress we are making in...
Business Wire
Techne (TECH) Misses Q3 Earnings and Revenue Estimates
Techne (TECH) delivered earnings and revenue surprises of -2.75% and -2.36%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Exelixis (EXEL) Tops Q1 Earnings Estimates
Exelixis (EXEL) delivered earnings and revenue surprises of +15.55% and -0.29%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Immunome, Inc. (the Company) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on May 1, 2026, the...
Business Wire
<
1
2
...
>
Advertisement|Remove ads.
Latest IMNM News
ViewImmunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors
Business Wire
4 Biotech Stocks Investors Should Watch in 2026
Zacks
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire
Advertisement|Remove ads.